Other
Anne Estrup Olesen
Total Trials
3
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
2(100.0%)
2Total
N/A(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT06110975Not ApplicableActive Not Recruiting
Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)
Role: lead
NCT04990986Not ApplicableCompleted
Co-Development and Evaluation of a Complex Intervention to Increase Medication Safety in Nursing Homes
Role: lead
NCT05721534Completed
Deprescribing and Health-related Effects
Role: lead
All 3 trials loaded